Abstract
Xuebijing injection may help reduce mortality and improve renal function in patients with SA-AKI. However, the certainty of evidence ranged from moderate to very low, underscoring the need for validation through large-scale, double-blind randomized controlled trials.
Introduction
Sepsis-associated acute kidney injury (SA-AKI) is a life-threatening complication occurring in up to 50% of septic patients, with mortality rates as high as 41%. Currently, treatment is primarily supportive, focusing on fluid resuscitation and renal replacement therapy, as no specific pharmacological "magic bullet" exists. This systematic review investigates Xuebijing (XBJ) injection—a standardized traditional Chinese medicine formulation—as a potential adjuvant therapy to improve clinical outcomes in SA-AKI.
Methodology
Researchers conducted a systematic review and meta-analysis of 18 randomized controlled trials (RCTs) involving 1,650 patients. The study followed PRISMA guidelines and utilized the GRADE system to evaluate evidence certainty. A key feature of the analysis was the use of Trial Sequential Analysis (TSA) to minimize the risk of false positives often associated with small sample sizes in meta-analyses.
Key Results and Clinical Insights
The meta-analysis revealed that XBJ injection, when added to conventional therapy, provides a multi-target advantage by addressing the "cytokine storm" and improving renal microcirculation.
Impact on Mortality and Renal Function
- Mortality Reduction: The study found a significant reduction in 28-day mortality, with a Risk Ratio (RR) of 0.82, representing approximately an 18% relative risk reduction.
- Renal Recovery: Patients receiving XBJ showed notable decreases in serum creatinine (MD -17.55 μmol/L) and blood urea nitrogen (MD -1.58 mmol/L), alongside increased urine output.
- Systemic Improvement: APACHE II scores, which measure the severity of critical illness, decreased by an average of 3.12 points in the XBJ group.
Safety and Evidence Quality
XBJ appeared to have a favorable safety profile, with adverse events like mild rash or nausea occurring in only 1.96% of patients and no serious drug-related reactions reported. However, the authors urge caution due to the quality of the underlying data.
Limitations
- Risk of Bias: Many included studies lacked clear details on blinding and allocation concealment, which may lead to an overestimation of treatment effects.
- Certainty of Evidence: Under the GRADE system, the certainty for most outcomes was rated as "low" or "very low" due to small sample sizes and study heterogeneity.
- Geographic Concentration: All trials were conducted in China, making it unclear if these results translate to more diverse genetic populations or different healthcare systems.
Conclusion
While Xuebijing injection is a promising adjuvant therapy for reducing mortality and improving kidney function in SA-AKI patients, the current evidence is not yet definitive. Large-scale, multi-center, double-blind RCTs are necessary before XBJ can be broadly recommended in international clinical guidelines.
Summary updated